Brief: Revive Therapeutics Announces LOI To Acquire Diagnamed’S Molecular Hydrogen Program
03/03/2025 14:42
March 3 (Reuters) - DiagnaMed Holdings Corp DMED.CD: REVIVE THERAPEUTICS ANNOUNCES LOI TO ACQUIRE DIAGNAMED’S MOLECULAR HYDROGEN PROGRAM Source text: ID:nGNXCG5WM Further company coverage: DMED.CD (Reuters.Briefs@thomsonreuters.com)
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure